Tania Dempsey, MD, discusses mast cell activation syndrome., which may be a consideration if a patient has not responded to anything else. Simple methods for treating and assessing patients are discussed.
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
Surgeon Commander VA Arun, INHS Asvini, Colaba, Mumbai, and Anil Handoo, MD, BLK-Max Superspeciality Hospital, Delhi, discuss systemic mastocytosis. They review classification and diagnostic criteria and the clinical…
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
